JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 282
- Registration Number
- NCT05178316
- Locations
- 🇺🇸
Clinical Innovations Inc., Santa Ana, California, United States
🇺🇸Global Medical Institutes, LLC: Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸Richmond Behavioral Associates, Staten Island, New York, United States
CPX-351 Real-World Effectiveness and Safety Study
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 147
- Registration Number
- NCT05169307
- Locations
- 🇬🇧
University Hospitals Derby and Burton, Derby, United Kingdom
🇬🇧Royal Marsden, London, United Kingdom
🇬🇧Bristol Royal Infirmary, Bristol, United Kingdom
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Conditions
- Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 920
- Registration Number
- NCT05152147
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorPoorly Differentiated Neuroendocrine CarcinomasUrothelial CancerMetastatic Solid TumorHomologous Recombination Deficient-Positive Malignancies Agnostic
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT05126433
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Bon Secours Hematology and Oncology, Greenville, South Carolina, United States
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT05122650
- Locations
- 🇺🇸
Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII), Los Angeles, California, United States
🇺🇸Innovative Research Of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Houston Methodist Hospital - Movement Disorders Clinic, Houston, Texas, United States
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
- Conditions
- Lennox Gastaut SyndromeDravet SyndromeTuberous Sclerosis Complex
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05044819
- Locations
- 🇺🇸
Clinical Trial Site, Winchester, Virginia, United States
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
- Conditions
- HER2-expressing Cancers
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT05027139
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸UC San Diego - Moores Cancer Center, La Jolla, California, United States
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
- Conditions
- Spasticity With Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT04984278
- Locations
- 🇨🇿
NeuropsychiatrieHK, Hradec Králové, Czechia
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Vithas Nisa Sevilla, Sevilla, Spain
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT04943952
Child and Adolescent Registry for Participants With Narcolepsy
- Conditions
- Narcolepsy
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT04899947
- Locations
- 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
🇺🇸Stanford University, Redwood City, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States